Total Payments
$6,968
2024 Payments
$116.83
Companies
50
Transactions
338
Medicare Patients
3,489
Medicare Billing
$715,243
Payment Breakdown by Category
Food & Beverage$6,691 (96.0%)
Education$277.51 (4.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,691 | 333 | 96.0% |
| Education | $277.51 | 5 | 4.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $906.69 | 38 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $605.85 | 49 | $0 (2024) |
| Amgen Inc. | $582.43 | 23 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $397.02 | 20 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $353.45 | 24 | $0 (2020) |
| GlaxoSmithKline, LLC. | $304.15 | 9 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $301.80 | 14 | $0 (2021) |
| PFIZER INC. | $293.81 | 17 | $0 (2023) |
| Astellas Pharma US Inc | $253.83 | 9 | $0 (2021) |
| Bayer HealthCare Pharmaceuticals Inc. | $213.38 | 10 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $116.83 | 6 | GlaxoSmithKline, LLC. ($56.62) |
| 2023 | $194.34 | 8 | Janssen Biotech, Inc. ($163.17) |
| 2021 | $1,941 | 83 | Janssen Biotech, Inc. ($222.08) |
| 2020 | $3,220 | 167 | Amgen Inc. ($405.26) |
| 2019 | $1,168 | 67 | Novartis Pharmaceuticals Corporation ($169.64) |
| 2018 | $223.82 | 5 | CSL Behring ($125.00) |
| 2017 | $103.84 | 2 | Janssen Biotech, Inc. ($79.99) |
All Payment Transactions
338 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.70 | General |
| Category: Oncology | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $19.69 | General |
| Category: ONCOLOGY | ||||||
| 07/23/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $19.25 | General |
| 07/11/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: ONCOLOGY | ||||||
| 06/11/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: ONCOLOGY | ||||||
| 01/31/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: ONCOLOGY | ||||||
| 09/28/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $23.07 | General |
| Category: Oncology | ||||||
| 08/21/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $31.09 | General |
| Category: Oncology | ||||||
| 07/24/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Oncology | ||||||
| 07/06/2023 | Boston Scientific Corporation | BodyGuardian (Device) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: CDS - BG Mini_RM | ||||||
| 06/15/2023 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $13.86 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $27.90 | General |
| Category: Oncology | ||||||
| 05/18/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $22.53 | General |
| Category: Oncology | ||||||
| 03/28/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $36.34 | General |
| Category: Oncology | ||||||
| 12/01/2021 | GlaxoSmithKline, LLC. | BLENREP (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 10/12/2021 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $106.01 | General |
| Category: Oncology | ||||||
| 08/05/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.14 | General |
| Category: Oncology | ||||||
| 08/04/2021 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $24.33 | General |
| Category: Oncology | ||||||
| 08/03/2021 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $20.93 | General |
| Category: Iron Deficiency Anemia | ||||||
| 08/02/2021 | Amgen Inc. | Kyprolis (Drug) | Food and Beverage | In-kind items and services | $30.80 | General |
| Category: Oncology | ||||||
| 07/26/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.44 | General |
| Category: Oncology | ||||||
| 07/12/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.40 | General |
| Category: Oncology | ||||||
| 07/03/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug), INVOKANA | Food and Beverage | In-kind items and services | $7.78 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/28/2021 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.68 | General |
| Category: Hematology | ||||||
| 06/24/2021 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 797 | 19,832 | $685,635 | $145,768 |
| 2022 | 32 | 1,126 | 32,280 | $1.1M | $281,151 |
| 2021 | 28 | 895 | 7,106 | $625,713 | $187,300 |
| 2020 | 25 | 671 | 2,639 | $344,123 | $101,024 |
Total Patients
3,489
Total Services
61,857
Medicare Billing
$715,243
Procedure Codes
112
All Medicare Procedures & Services
112 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 26 | 2,580 | $214,407 | $47,466 | 22.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 122 | 253 | $121,718 | $26,166 | 21.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 42 | 101 | $61,187 | $12,209 | 20.0% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 11 | 11,550 | $45,362 | $10,157 | 22.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 37 | 64 | $43,012 | $9,413 | 21.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 67 | 114 | $30,676 | $6,592 | 21.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 65 | 79 | $26,945 | $5,644 | 20.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 60 | $17,321 | $3,977 | 23.0% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 11 | 2,860 | $17,473 | $3,914 | 22.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 21 | 21 | $17,236 | $3,780 | 21.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 47 | 184 | $17,095 | $2,573 | 15.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 12 | 36 | $10,605 | $2,130 | 20.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 72 | 167 | $13,470 | $2,008 | 14.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 17 | 17 | $7,777 | $1,850 | 23.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $8,722 | $1,716 | 19.7% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 27 | 68 | $5,974 | $1,252 | 21.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 13 | 42 | $5,625 | $1,071 | 19.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 14 | 39 | $5,722 | $1,023 | 17.9% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 14 | 29 | $3,896 | $894.36 | 23.0% |
| 36591 | Collection of blood sample from implanted device | Office | 2023 | 16 | 28 | $3,056 | $701.96 | 23.0% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 11 | 22 | $4,840 | $655.16 | 13.5% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 15 | 31 | $2,137 | $356.81 | 16.7% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 24 | 600 | $262.52 | $58.78 | 22.4% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 22 | 764 | $258.36 | $57.85 | 22.4% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 19 | 47 | $263.22 | $54.17 | 20.6% |
About Mohamad Barakat
Mohamad Barakat is a Internal Medicine healthcare provider based in Huntington Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/04/2008. The National Provider Identifier (NPI) number assigned to this provider is 1558534131.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mohamad Barakat has received a total of $6,968 in payments from pharmaceutical and medical device companies, with $116.83 received in 2024. These payments were reported across 338 transactions from 50 companies. The most common payment nature is "Food and Beverage" ($6,691).
As a Medicare-enrolled provider, Barakat has provided services to 3,489 Medicare beneficiaries, totaling 61,857 services with total Medicare billing of $715,243. Data is available for 4 years (2020–2023), covering 112 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Huntington Beach, CA
- Active Since 04/04/2008
- Last Updated 08/11/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1558534131
Products in Payments
- IMBRUVICA (Drug) $600.29
- OPDIVO (Biological) $546.88
- KEYTRUDA (Biological) $377.14
- Imbruvica (Drug) $276.79
- DARZALEX (Biological) $203.91
- Stivarga (Drug) $176.93
- GILOTRIF (Drug) $172.93
- BLENREP (Biological) $153.13
- Kyprolis (Drug) $145.37
- EVENITY (Biological) $136.95
- PADCEV (Biological) $134.45
- XOSPATA (Drug) $129.94
- PROMACTA (Drug) $129.82
- Afstyla (Biological) $125.00
- JAKAFI (Drug) $124.46
- ZEJULA (Drug) $122.35
- Vectibix (Biological) $118.49
- SOMATULINE DEPOT (Drug) $111.63
- BRUKINSA (Drug) $110.96
- FOTIVDA (Drug) $106.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Huntington Beach
Dr. John Homan, Md, MD
Internal Medicine — Payments: $228,916
Internal Medicine $228,916
Ratul Chatterjee, M.d, M.D
Internal Medicine — Payments: $24,688
Internal Medicine $24,688
Dr. David Tsong, M.d, M.D
Internal Medicine — Payments: $18,433
Internal Medicine $18,433
Dr. Robby Ayoub, Md, MD
Internal Medicine — Payments: $18,079
Internal Medicine $18,079
Mr. Joseph Nassir, Md, MD
Internal Medicine — Payments: $16,011
Internal Medicine $16,011
Khadija Mayet, Md, MD
Internal Medicine — Payments: $12,571
Internal Medicine $12,571